We are pioneering healthcare to improve patients’ lives around the world
Our Purpose
Making medicines more affordable, more available, and better than before
We, at Tiefenbacher Group, are driven by a deep sense of purpose: since 1963 we are pioneering healthcare to improve patients’ lives around the world.
We believe that there are always ways to make pharmaceuticals more affordable, more available and better than before. This belief drives our curiosity and inspires us to continuously challenge the status quo. We love to pave new ways and to push frontiers to make a meaningful impact on patients’ lives.
We work together as one Tiefenbacher Group, providing best-in-class solutions along the entire pharmaceutical value chain. We distribute raw materials and develop, manufacture, and register affordable, value added, and innovative medicines. This broad competence enables us to pioneer healthcare holistically as we can connect ideas and expertise to create better healthcare solutions.
Our company values: curiosity driven – excellence focused – patient centered
Always challenging the status quo – this is how we work, this is how we think
Our three values define who we are and what special attitudes we have. They are central to how we behave as individuals, and collectively as an organization to achieve our purpose of making pharmaceuticals more affordable, more available, and better than before.
Our purpose and our values tie us together across functions, across business units, and across the world. By working together as one Tiefenbacher Group we tap into our full potential and stay at the forefront of our field to shape a healthier tomorrow.
Organization Structures
Connected and collaborating in agile structures
Our B2B and B2C business unites is systematically oriented toward our operational business. Our agile cross-functional company structure makes us stronger and better to change tomorrow’s health together.
Our company structure
We, at TIEFENBACHER GROUP, have often demonstrated to excel in our field, to retain talent, and to innovate fastest. Our broad competence and vertical company structures enables us to pioneer healthcare holistically. We are pushing beyond what’s possible – always from a patient-centric approach – and are bringing forward novel healthcare solutions for people around the world.
corporate responsibility
Improving patients’ lives through sustainable business
At Tiefenbacher, ESG is embedded in our business strategy — not treated as a checkbox. Environmental, Social, and Governance principles guide how we innovate in sustainable manufacturing, improve access to better healthcare, and uphold transparent, ethical operations.
Our ESG approach helps us generate long-term prosperity and create value for people and the planet. We proudly support the United Nations Sustainable Development Goals (SDGs) and are committed to taking climate action in our own operations and, in future, along our pharmaceutical value chain.
Rooted in our core values and guided by our purpose of improving patients’ lives, sustainability shapes how we operate and strengthen our business for the future.
Environmental Commitment: Climate action
Reducing our carbon footprint
The climate, nature and our health are deeply interconnected. We’re decarbonizing our operations and driving action at scale to accelerate the delivery of net-zero, sustainable healthcare.
Progress highlights: 78% reduction in Scope 1 and 2 greenhouse gas emissions to previous year, 23% of total electricity by photovoltaic system
Focus SDG
Clean operations and supply chains
Environment Commitment: Climate action
Our Progress
Our Planet
Massive emission reductions and savings
Green electricity as main driver
In June 2024, our new photovoltaic system in Cyprus went into operation. On average, it now supplies 23% of our total electricity consumption and up to 32% at peak performance. At the same time, we transitioned to 100% green electricity (wind power) across all our sites, reducing our CO₂ emissions by more than 5,000 tons per year.
Combined, these measures enabled us to achieve a 78% reduction in our Scope 1 and Scope 2 carbon footprint compared to the previous year.
We are also investing in a solar water heater project in India, which reduces local greenhouse gas emissions. Through Gold Standard-certified carbon credits generated by this initiative, we compensate for the climate impact of all our business flights.
These steps represent our tangible contribution to SDG 13 (Climate Action). Our significant reduction in greenhouse gas emissions directly supports the long-term climate protection strategies of Germany, Cyprus and India—each aligned with the commitments of the Paris Agreement. This is how we actively contribute to achieving SDG 13.2.
Sustainable packaging materials for long-term responsibility
Creating meaningful impact requires rethinking every layer of pharmaceutical packaging—from transport and secondary packaging to the most prominent and complex of all: primary packaging.
At Tiefenbacher, we focus on the pharmaceutical blockbusters: high-volume medicines that contribute most to global packaging waste. Improvements here deliver the biggest impact. Even small enhancements scale up to hundreds of thousands of units, significantly reducing material consumption and waste.
After extensive and challenging development work, we are proud to announce a major breakthrough: our new monomaterial blister. This innovation marks a significant step forward in sustainable primary packaging.
In parallel with this milestone, we continue to minimize waste and improve material efficiency across our operations. These efforts support SDG 12.5, which calls for reducing waste through prevention, reduction, recycling and reuse. Our procurement strategy is aligned with SDG 12.2, prioritizing sustainable and ethically sourced materials to ensure the responsible and efficient use of natural resources.
Together, these actions move us closer to a future where pharmaceutical packaging is both effective and environmentally responsible.
Social: Wellbeing, Growth and Development
Health and Wellbeing for All
Health and wellbeing are at the heart of our purpose and our long-term sustainability strategy. We are dedicated to expanding access to high-quality healthcare globally. We are also supporting disadvantaged children in the communities where we live and operate.
Within our organization, we foster an inclusive, safe and healthy work environment. Employee wellbeing is a core driver of performance and innovation, enabling us to maintain high-quality standards, support sustainable growth, and attract and retain top talent in a competitive global market.
The wellbeing of patients, communities and employees forms the foundation of our social responsibility. By integrating these commitments into our daily operations, we help strengthen local health systems, support more resilient communities, and build a sustainable, future-ready workforce.
Focus SDG
Social
Social obligations: Health and Wellbeing for All
Key Facts
Social Key initiatives
We deepen our impact in the communities where we live and work
Supporting children in Hyderabad (India)
We are committed to creating meaningful, long-term impact in the communities where we live and work. In Hyderabad /India, we support children through initiatives focused on health, education, and sanitation.
We are proud to sponsor 75 children (ages 6–10) at the Sardar Vallabhai Patel School, a Tiefenbacher-supported institution affiliated with the Government of Telangana. This partnership helps provide young learners with better opportunities, improved infrastructure, and a supportive environment in which to thrive.
Promoting decent work and inclusive growth
Furthermore, our inclusive employment practices, fair wages, and commitment to employee wellbeing directly support SDG 8.5, promoting productive employment and decent work for all. By ensuring safe and secure working conditions, we contribute to SDG 8.8, fostering a workplace culture built on respect, equity, and continuous development. These efforts help strengthen our organization while reinforcing our responsibility to our people and the broader community.
Supporting India against Black Fungus after COVID-19
During India’s severe second COVID-19 wave, cases of Black Fungus (Mucormycosis) rose dramatically among recovering patients. To help respond quickly, Tiefenbacher Pharmaceuticals rapidly adapted production to supply Posaconazole tablets, a key treatment for this life-threatening infection.
This action reflects our contribution to SDG 3.4.1, reducing premature mortality from major diseases. Globally, we provide a broad range of affordable generic medicines — including treatments for cardiovascular diseases, cancer, diabetes and chronic respiratory diseases—as well as an extensive portfolio of APIs supporting these therapeutic areas.
Through accessible, high-quality medicines, we help strengthen global health outcomes.
Governance: Transparency and accountability for prosperity
Operating with the highest standards of ethics and values
We uphold strong governance through a value-driven culture, clear policies, and independent board oversight. Our practices align with global standards to ensure transparency, accountability, integrity, and ethical conduct across all operations.
We also prioritize responsible product stewardship, ensuring the safety, efficacy, and quality of our products throughout their entire lifecycle.
Key facts: PSCI members, EcoVadis silver medal
Focus SDG:
Governance
Governance: Responsible growth for long‑term value and prosperity
Key Facts
Governance Key initiatives
Responsible growth for long term value and prosperity
Uniform and comparable industry standards
We have been a member of the Pharmaceutical Supply Chain Initiative (PSCI) since May 2022. PSCI brings together 85 member companies worldwide, representing approximately USD 1.2 trillion — around 70% of global pharmaceutical revenues. Through this platform, we collaborate with industry leaders to define, strengthen and advance responsible value chain practices using a unified voice.
We also participate in EcoVadis, one of the world’s most trusted sustainability ratings, covering more than 150,000 companies across industries and regions. Earning our second consecutive Silver Medal places us among the top 10% of EcoVadis-rated companies in terms of sustainability performance over the past year.
Collaboration is essential to achieving meaningful progress. By working closely with suppliers, partners, customers and industry organizations, we build strong, transparent, and accountable relationships that reinforce sustainability throughout the value chain. These partnerships help us jointly advance shared sustainability objectives in line with SDG 17. Our active participation in CSR and industry initiatives demonstrates our commitment to SDG 17.16, which focuses on multi-stakeholder partnerships that mobilize knowledge, expertise, and resources to support sustainable development.
Sustainable and resilient supply chains
Although we are not legally subject to the German Supply Chain Due Diligence Act (LkSG) or the EU Corporate Sustainability Due Diligence Directive (CSDDD), we voluntarily conduct regular risk analyses of all our suppliers in alignment with the requirements of these regulations. As part of our abstract risk assessment on human rights, labor rights and environmental risks, we have screened 100% of our tier-1 suppliers. For suppliers identified as higher risk, we carry out additional due diligence measures such as targeted questionnaires and on-site audits.
Since 2022, we also operate a secure, confidential whistleblower platform for reporting potential ESG violations. It is accessible to employees and all external stakeholders and reflects Tiefenbacher’s commitment to transparency, accountability and integrity.
Through supplier audits and responsible sourcing policies, we support SDG 8.7, taking proactive steps to prevent forced labor and exploitative practices within our value chain. Our supplier evaluation processes promote fair labor standards, human rights protection, and safe working conditions, contributing to inclusive, ethical and sustainable economic growth. Certifications such as ISO 45001 (Occupational Health and Safety) and SA8000 (Social Accountability) serve as key indicators of responsible performance for our suppliers.
We also integrate environmental management systems such as ISO 14001, EMAS, and ISO 50001 into our supplier assessments to encourage emissions reduction, efficient energy use and effective environmental management across the supply chain. These measures help strengthen resilience and support the transition toward more sustainable and climate-aligned global supply networks.
Tiefenbacher Group achieves EcoVadis silver medals
Proven commitment to sustainable business
We are excited and proud to announce that we have achieved two silver medals in the recent EcoVadis Sustainability ratings, placing the company among the top 15% of all rated companies worldwide. The achievement of the silver ratings represents an important recognition that underlines Tiefenbachers commitment to Corporate Social Responsibility based on four main areas: Environment, Labour & Human Rights, Ethics and Sustainable Procurement.
Governance & Business Ethics
Responsible corporate governance
We are committed to responsible corporate governance – throughout our whole organization and pharmaceutical value chain.
Our Environmental Policy, Human Rights & Labor Policy as well as our Sustainable Procurement Policy are available upon request. For these documents or any questions regarding our sustainability journey or other ESG-related inquiries, please send an email to sustainability@tiefenbacher.com.
Further details
For us at Tiefenbacher Group, compliance means more than adhering to legal requirements, voluntary obligations and internal company guidelines. Compliance is a question of attitude: reliability, honesty, credibility, and integrity are part of our DNA and the basis of our sustainable business success.
The Code of Conduct and the Whistleblower Platform are two important components of our corporate governance.
Our Code of Conduct describes how we want to do business at TIEFENBACHER GROUP. It provides guidance on how to deal with the most important integrity and legal issues in our daily work – with our colleagues, our customers, our business partners, and other third parties.
With our Whistleblower Platform Tiefenbacher Group offers employees and external stakeholders the opportunity to report violations of legal provisions and internal company regulations anonymously. Every report is examined in detail by an external body, suspicious cases are investigated, and any infringements are consistently pursued. Our Whistleblower Portal is a dedicated communication channel operated by a third party and available 24 hours a day, 365 days a year
Our History: Pioneering healthcare since 1963
Our milestones and continued growth at Tiefenbacher
From a distributor of Active Pharmaceutical Ingredients (APIs) to a purpose-driven healthcare company with a global footprint. We have always been powered by a strong commitment to make a difference with our products and services. Founded in 1963 as the world’s first exclusive agency for active pharmaceutical ingredients (APIs), Tiefenbacher has been grown into a leading healthcare company providing innovative and best-in-class solutions along the entire pharmaceutical value chain.
From initial idea to market entry: Today we distribute APIs and develop, manufacture, and register finished dosage forms (FDFs). In over 60 years of our company history, we have shown an outstanding track record in anticipating new developments as well as launching new businesses.
2026
Expansion of production block 1 at Tiefenbacher Laboratories India
2025
Opening of new R&D centre at Tiefenbacher Laboratories India
2024
Opening of new high potency site at Tiefenbacher Laboratories India
2021
Site Expansion at Delorbis Cyprus
2020
Start of Oysta (Drug-eHealth combination)
2019
First NCE approval for innovative sleeping medicine
2016
Foundation of Tiefenbacher Medical Devices
2014
Launch of axunio Pharma (Branded Pharmaceuticals)
2014
Foundation of AET Pharma Inc. USA
2009
Acquisition of Delorbis Cyprus (Manufacturing / Branded Pharmaceuticals)
2003
Opening of AET Laboratories India (R&D and Manufacturing)
1995
First generic drug development of finished dosage form
1963
Foundation by Alfred E. Tiefenbacher (API distribution)
Pioneer of the pharmaceutical industry
Our founder Alfred E. Tiefenbacher – a family-owned company since 1963
Our entrepreneurial spirit is firmly anchored in our founder and owner family since 1963.
The foundation of TIEFENBACHER GROUP´s success story was the pioneer spirit of the company´s founder and namesake Alfred E. Tiefenbacher (*1917, +1993). Until today his unique entrepreneur mind is our driving force of achieving better health solutions by always challenging the status quo.
As we have growing, we are proud to have maintained the agile, entrepreneurial spirit on which we were founded, continuously evolving with our customers and the industry to expand our services and network. Through all of this, we continue to exercise the same level of flexibility and responsiveness that is embedded in our DNA. This combination translates to superior quality to make pharmaceuticals more affordable, more available, and better than before.
